טוען...
Targeting PDZ Binding Kinase Is Anti-tumorigenic in Novel Preclinical Models of ACC
Adrenocortical carcinoma (ACC) is an aggressive orphan malignancy with less than 35% 5-year survival and 75% recurrence. Surgery remains the primary therapy and Mitotane, an adrenolytic, is the only FDA approved drug with wide range toxicities and poor tolerability. There are no targeted agents avai...
שמור ב:
| הוצא לאור ב: | Endocr Relat Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6938568/ https://ncbi.nlm.nih.gov/pubmed/31325906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-19-0262 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|